The Entrepreneurship of Psychedelic Negativity: Psymposia, Trauma, Iatrogenic Harm, and Prohibition 2.0
Contemporary Drug Problems July 10, 2026 Oliver Davis, Sophie Casey
This article outlines a skeptical appraisal of Psymposia, a small but influential self-appointed psychedelics “watchdog” organization based in the United States of America, which played a significant role in blocking regulatory approval for MDMA as a treatment for PTSD in 2024. Contextualized close analysis of its “Power Trip” podcast series, which focused on sexual abuse in the psychedelic...